Rationally Designed TLR4 Ligands for Vaccine Adjuvant Discovery

Rationally Designed TLR4 Ligands for Vaccine Adjuvant Discovery

ABSTRACT Adjuvant properties of bacterial cell wall components like MPLA (monophosphoryl lipid A) are well described and have gained FDA approval for use in vaccines such as Cervarix. MPLA is the product of chemically modified lipooligosaccharide (LOS), altered to diminish toxic proinflammatory effe...

Full description

Bibliographic Details
Main Authors: Kelsey A. Gregg, Erin Harberts, Francesca M. Gardner, Mark R. Pelletier, Corinne Cayatte, Li Yu, Michael P. McCarthy, Jason D. Marshall, Robert K. Ernst
Format: Article
Language:English
Published: American Society for Microbiology 2017-07-01
Series:mBio
Subjects:
TLR4
adjuvants
immunomodulation
innate immunity
lipid A
lipopolysaccharide
Online Access:https://journals.asm.org/doi/10.1128/mBio.00492-17

Internet

https://journals.asm.org/doi/10.1128/mBio.00492-17

Similar Items